Navigation Links
Cohera Medical Secures $16.1 Million in Series B Financing
Date:10/17/2008

PITTSBURGH, Oct. 17 /PRNewswire/ -- Cohera Medical Inc. today announced it has secured $16.1 million in a Series B financing for the ongoing development of TissuGlu(R), a novel surgical adhesive for application in plastic surgery.

The financing, which was led by Bradford Capital Partners, included participation from existing investors led by Kern Whelan Capital, LLC. The angel financing provides the company with sufficient capital to advance TissuGlu into clinical trials, which are expected to begin early next year.

"Kern Whelan Capital is delighted to support this second round of financing by doubling our initial investment," said Jay Kern, operating partner. "We believe there is a huge market potential in many applications for Cohera's products."

"TissuGlu has great promise in tummy tuck and other plastic surgery indications," said Marty Calihan, partner, Bradford Capital Partners. "Moreover, the company's core technology has significant potential for other uses, including mesh fixation and orthopedic applications. We view Cohera Medical's unique lead product and technology chassis as having tremendous potential to meet multiple needs of surgeons and their patients for which there are few options today."

Patrick Daly, chief executive officer of Cohera Medical, said "Our closing of this significant angel financing round in the current economic environment is a testament to the potential of our surgical adhesive technology. The financing gives us the capital to move forward with our clinical program for TissuGlu and affords us the opportunity to continue development of our other products."

About Cohera Medical

Cohera Medical Inc. is a Pittsburgh-based company that is developing a revolutionary line of wound management products and surgical adhesives. Cohera Medical's products are based on a unique chemical design that is purely synthetic, easy to use, biocompatible and fully resorbable. The company's lead product in development, TissuGlu, is a sprayable bonding agent for plastic surgery procedures. TissuGlu adheres flaps of tissue after surgical procedures, eliminating the spaces where fluid accumulates and reducing wound drainage. Cohera Medical is also developing surgical adhesives targeting mesh fixation and small bone fixation, which will fill similar market needs in both orthopedics and general surgery. For more information, visit http://www.coheramed.com. TissuGlu and the other Cohera products have not yet been approved for medical use by the Food and Drug Administration (FDA) in the U.S. or by any other country's regulatory authority.

Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.


'/>"/>
SOURCE Cohera Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cohera Medical Names Richard L. Wonsettler as Companys First CFO
2. Data Published in Plastic and Reconstructive Surgery Show Cohera Medicals Surgical Adhesive, TissuGlu(R), Prevents Seroma Formation in Animal Abdominoplasty Model
3. KePROs Chief Medical Officer to Present and Participate in Physician Roundtable at McKesson Health Solutions Conference
4. InHealth awards grants to study impact of medical diagnostics and devices on patients, health care
5. Clinicians in Netherlands Treat Lung Cancer Patients Using New RapidArc Radiotherapy Technology from Varian Medical Systems
6. Houston Northwest Medical Center Receives Clinical Excellence Awards for Several Service Lines
7. LegalView Reintroduces its Medical Malpractice Information Portal with Updated Links to Finding Immediate Legal Assistance
8. Sutter Medical Center Breaks Ground on Historic Womens and Childrens Center
9. Integrated Medical Systems Receives FDA Clearance for Worlds First Suitcase Intensive Care Unit
10. Frost & Sullivan Awards Infor-Med for its Electronic Medical Record Technology
11. Geisinger Medical Center earns prestigious Magnet designation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... August 22, 2017 , ... ... Medicine recently spoke at a popular international aesthetics conference for medical professionals about ... restoring his patients’ health and his growing practice. , Dr. George K. ...
(Date:8/22/2017)... TX (PRWEB) , ... August 22, 2017 , ... Five Star Glass is new to ... provide repair and replacement of auto glass for most makes and models, in Grand Prairie, ... the USA. , They have been a family owned business for the past 40 ...
(Date:8/22/2017)... ... ... “Glimpses Of Light”: is a unique and thought inspiring guide toward self-discovery ... published author, J.M. Shepherd, a writer, teacher, traveler, and metaphysician, the author has spent ... shares, “Love is one of the least understood and yet most sought-after pleasures known ...
(Date:8/21/2017)... ... August 22, 2017 , ... PracticeMatch, a company that ... healthcare employers connect with physicians and advanced practitioners like nurse practitioners and ... in August through November of this year. The online career fairs will allow ...
(Date:8/21/2017)... , ... August 21, 2017 , ... ... announced that it has become the Official Technology Partner of North Country Region ... (Advanced Event Systems) volleyball software, along with providing sport management software to ...
Breaking Medicine News(10 mins):
(Date:8/14/2017)... and PETACH TIKVAH, Israel ... (NASDAQ: BCLI), a leading developer of adult stem cell ... second quarter ending June 30, 2017. ... of preparing for our pivotal Phase 3 trial to ... Lebovits , President and Chief Executive Officer of BrainStorm. ...
(Date:8/8/2017)... Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a ... reports its financial results for the second quarter ended ... the second quarter 2017 and to date: ... development programs for the Company,s lead project, BL-8040: ... study with BL-8040 as novel stem cell mobilization treatment ...
(Date:8/7/2017)... WARSAW, Ind. , Aug. 7, 2017 Zimmer ... in musculoskeletal healthcare, today announced that its Board of Directors ... stockholders for the third quarter of 2017. ... will be paid on or about October 27, 2017 to ... September 22, 2017.  Future declarations of dividends are subject to ...
Breaking Medicine Technology: